Document ba9bdDLD8ez1wrEVeYBkjLYR6

FC Core Team 2004 2005 Project / Process Priorities Client-Attorney Priveleged W ork Product: Do not copy or distribute Strategy /BCY's Project & Processes Com m and the science: exposure, analytical, fate, effects, human health and ecological D evelop and maintain internal 3M analytical capability - telom ers and ECF chem istries Develop strategy for external science with respect to telom ers and ECF chem istries Understand TFA risk assessm ent work D eve lop and im p le m en t a 3M Publication Plan: R esearch to be p ub lish ed as co m p le te d in ope n scien tific literature - health research D eve lop and im p le m en t a 3M Publication Plan: R esearch to be p ub lish ed as co m p le te d in ope n scien tific literature - environm ental. C reate a process to track global FC related work outside o f 3M (Public universities, governm ent institutes, etc.,including literature and funding). D evelop process to m onitor scientific literature for new data with respect to health effe cts and environm ental issues Track d evelopm ents o f biom onitoring by C enters for D isease C ontrol (C D C ). If necessary, hold w orkshop for third party spokespersons and include preparation for Science A dvisory Panel public m eetings R evisit 3M S cie n tific A d visory Board: D efine role, if any, o f 3M S A B in the E P A P F O A risk a sse ssm e n t and P F O S IR IS p ro ce sse s. Develop strategy to present to EPA SAB on PFO A risk assessm ent. Include industry team . R eestablish international regulatory-scientific-legal-public affairs infrastructure-identify resources, responsibilities and relationships to US Core Team. T rack age nd as for, be aware o f and participate in scien ce and regulatory co n fe re n ce s. Develop strategy to build stronger (International) OUS science representation at the Research Science Level Develop strategy to build stronger (International) OUS science representation at the Science Policy Level Develop and im plem ent a program to understand the toxicology and environmental m echanism s for support o f the PFOS, PFOA, Review the adequacy o f the epidem iology data and address any gaps. Evaluate P F O A p re cursors in other products, if any. Review the adequacy o f the biom onitoring data and address any gaps. Achieve neutral to positive regulatory agency outcomes: findings and actions Develop an Asian strategy for PFOS regulation, Japan being first. Develop an Asian strategy for PFOA regulation, Japan being first. Develop an EU strategy for PFOS science policy Develop an EU strategy for PFOA science policy Ensure sound science and appropriate risk management at EU level by staying engaged with UK-DEFRA Risk Reduction Strategy Canada - PFOS Environmental Assessment: Continue to maintain good relations with Environment Canada through regular contacts and strive to ensure that the final assessment - and any actions based thereon - are accurate and fair. OECD: Continue to monitor OECD for further regulatory developments. United Nations Environmental Programme (UNEP): Continue to monitor UNEP activities for further PFOS/PFOA-ielated Track Activities of Sweden Chemicals Inspectorate. Ensure sound science and appropriate risk management by staying engaged with Review historical use of IRIS reviews by international, national, state and local authorities. Look at related cases (e.g. PCB's) and Monitor (US) federal and state legislative and regulatory activities related to FC's. Biomonitoring bill in CA, etc. Prepare and submit final perfluorooctanyl phase-out summary to EPA when 3M inventories are substantially expired, Establish and strengthen dialogue with EPA's ORD (Dr. Preuss) and management (C. Auer, S. Johnson) and other parties outside EPA who will be influential in PFOS and PFOA risk assessment processes and other science policy matters affecting FC's. US political strategy: Update the political strategy document and key contacts listing and implement agreed plan. Satisfy C8 regulatory commitments Satisfy 3M letter of Intent (LOI) commitments Satisfy Dyneon letter of Intent (LOI) commitments Society of Plastics Industry (SPI): Work successfully with FMG and SPI to complete ECA negotiations and implement LOI/ECA commitments. Support Association of Plastics Manufacturers in Europe (APME) toxicology and environmental study programs. Set up internal management review for Decatur site monitoring issues. Set up internal management review for Gendcrf site monitoring issues. Set up internal management review for Cottage Grove site monitoring issues. Satisfy MOU Process - 3M Site Monitoring - PFOA Antwerp groundwater/site assessment: Complete risk assessment. Cottage Grove-Drinking Water (MN Dept, of Health): Determine monitoring and process control requirements. Complete 8(e) Self Disclosure and settlement Phase IV audit. Monitor and prioritize external trends and organizations affecting FC's Monitor and understand future direction (globally) of NG O's and partnerships. Effective communication. Media attention to PFO A Risk Assessm ent/SAB Review: W ork with industry group to take the lead on defense o f PFO A and science. Maintain preparedness in order to respond to P F O A m edia coverage o f risk assessm ent. Maintain talking points for ECA/LOI and other US regulatory activities. Maintain 3M Sum itom o talking points for P F O A /S A B . Develop a m essage testing m echanism for talking points - particularly in Europe Maintain talking points: C4 chemistry. Maintain talking points: 8(e) voluntary com pliance audit. Maintain talking points: Decatur litigation. Assure FC Enterprise Risk Management organizational health. Conduct a resource review (current and prospective) for ongoing issue management needs. C4 Regulatory and Product Stewardship Strategy Maintain dialogue with EPA and international regulators on C4 chemistry. consent orders at the earliest possible tim e. Include E P A 1NTP class study activity. Catalog all current 3M C4 product applications. P ro ce ss and control plan needed. Continue phaseout trajectory (C8 use/em ission/exposure reduction) Review the adequacy of the C4 polymer degradation data and address any gaps. Evaluate scenarios for full com mercialization of PFBS (modelling project) Develop a reference dose for C4 to determ ine if environmental/biomonitoring need to be done. Im prove review process o f all C4 com m ercialization e ffo rts in 3M. Prepare a summary of existing perfluorooctanyl inventories across 3M's business units and establish tim etables for consum ption or use of inventories. Review PFOS exposure assessm ents and related information. Develop strategy about monitoring of possible source areas, based on existing PFOS exposure assessm ents and modelling.